National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute on Alcohol Abuse and Alcoholism (NIAAA) sits in the top decile of US sponsors by registered trial count (#253 of 15,742 sponsors by registered trial count).
National Institute on Alcohol Abuse and Alcoholism (NIAAA): 93 sponsored US clinical trials, 16 recruiting.
National Institute on Alcohol Abuse and Alcoholism (NIAAA) sponsors 93 registered US clinical trials on ClinicalTrials.gov, 16 of them currently recruiting, and 71 completed. 9 of these trials are in Phase 3-4 (later-stage) and 58 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alcoholism, with 11 trials.
Top-decile sponsor footprint
National Institute on Alcohol Abuse and Alcoholism (NIAAA) ranks in the top decile of sponsors by registered trial count (#253 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
71 of 77 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
93 total, page 1 of 2
Tirzepatide in MetALD
NCT07046819
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
NCT07559500
Human Laboratory Study of Apremilast for Alcohol Use Disorder
NCT07325266
Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors
NCT06819189
Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder
NCT06269627
Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms
NCT06484075
Individual Variations of Taste and Smell Perception in Alcohol Use Disorder (AUD)
NCT05677321
Mechanisms Underlying Individual Variations of Taste and Smell in Obesity
NCT04714892
Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
NCT04781322
COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study
NCT04391816
Nicotinic Receptor Genetic Variation and Alcohol Reward
NCT03294460
Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)
NCT03407079
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
NCT02535702
NIAAA Natural History Protocol
NCT02231840
Characterization Imaging Instruments in Alcoholics and Non-Alcoholics
NCT02108080
Behavioral and Functional Task Development, Implementation, and Testing
NCT02108054
Intranasal Oxytocin for the Treatment of Alcohol Use Disorder
NCT03878316
Human Laboratory Study of ASP8062 for Alcohol Use Disorder
NCT05096117
Effect of Acute Alcohol Intoxication on Neural Processes During Decisions to Engage in HIV Risk Behaviors
NCT04360018
HLAB-002 of ANS-6637 for Alcohol Use Disorder
NCT03970109
Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI
NCT03326245
Ketogenic Diet (KD) in Alcoholism
NCT03255031
Brain Dopaminergic Signaling in Opioid Use Disorders
NCT03190954
Human Laboratory Study of Varenicline for Alcohol Use Disorder
NCT03035708
A Novel Compound for Alcoholism Treatment: A Translational Strategy - Part II
NCT02707055
Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation
NCT02639273
Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People
NCT02669225
Study of Structural Imaging
NCT02564991
Epi-Genetic Modulators of Fear Extinction in Alcohol Dependence
NCT02438969
Human Brain Mapping of the Apparent Diffusion Coefficient (ADC) During Sleep and Wakefulness
NCT02311374
Reliability of the Human Brain Connectome
NCT02193425
HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder
NCT02252536
Brain Inflammation and Function in Alcoholism
NCT02233868
Neural Substrates of Approach-Avoidance Conflict
NCT02119624
Neuroimaging, Omega-3 and Reward in Adults With ADHD (NORAA) Trial
NCT02156089
A Novel Compound for Alcoholism Treatment
NCT02039349
Genetic Effects on Dopamine Response to an Opiate
NCT01878006
ABT-436 for Alcohol Dependence
NCT01613014
Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers
NCT01779024
Baclofen for Treating Anxiety and Alcoholism
NCT01751386
Role of Proinflammatory Signaling in Alcohol Craving
NCT01631630
Measuring Effects of Alcohol on Brain Chemistry
NCT01492933
Genetics of the Acute Response to Alcohol in Social Drinkers
NCT01375556
Varenicline for Alcohol Dependence
NCT01146613
National Epidemiologic Survey on Alcohol and Related Conditions-III
NCT01273220
Dietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body Composition
NCT01251887
Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^
NCT01227980
CRF1 Antagonist GSK561679 in Alcoholism
NCT01187511
Levetiracetam XR in Very Heavy Drinkers
NCT00970814
The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD
NCT00896038
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
| Phase 2 | 37 |
| Phase 3 | 1 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the National Institute on Alcohol Abuse and Alcoholism (NIAAA) pipeline
16 recruiting of 93 indexed (17% open); 71 completed (76%).
Phase mix: 9 late (III/IV) vs 58 early (I/II) (early-phase heavy).
Top condition: Alcoholism (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute on Alcohol Abuse and Alcoholism (NIAAA): open-pipeline peers nationwide
Peers matched on 93 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
National Institute on Alcohol Abuse and Alcoholism (NIAAA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 93 trials (± recruiting share)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · 93 trials · 13% recruiting
- Roxane Laboratories · 93 trials · 0% recruiting
- Colorado State University · 94 trials · 21% recruiting
- Endeavor Health · 94 trials · 20% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Emory University · 17% recruiting · 1,208 trials
- Baylor Research Institute · 17% recruiting · 180 trials
- Hunter College of City University of New York · 17% recruiting · 29 trials
- Ochsner Health System · 17% recruiting · 29 trials
Related
What to do with this National Institute on Alcohol Abuse and Alcoholism (NIAAA) page
93 registered trials is a research-attention snapshot, not an endorsement of National Institute on Alcohol Abuse and Alcoholism (NIAAA) or any single study.
- 16 of National Institute on Alcohol Abuse and Alcoholism (NIAAA)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Alcoholism is the condition National Institute on Alcohol Abuse and Alcoholism (NIAAA) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alcoholism trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Institute on Alcohol Abuse and Alcoholism (NIAAA) pipeline card: 93 registered trials from official public datasets.Report a data error.